Physicians thought that newly diagnosed patients, sicker patients—those who had been hospitalized for diabetes, were currently using insulin, or who had any comorbid condition—and patients who were nonadherent to treatment were most likely to benefit from CES use. The gene discussed is INS; the disease is diabetes mellitus.